FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.genomics-reporting
Resource TypeProcedure
IdProcedure-genomicstudy-trio2.json
FHIR VersionR4

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: Procedure genomicstudy-trio2

Profile: Genomic Study

Genomic Study Analysis Extension: Procedure: extension = GRCh38,->Father Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 6789-11111 (use: temp, )),->Mother Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 0987-11111 (use: temp, )),Parental Sequence Variation Detection Using Next Generation Sequencing,->Procedure Sequencing of entire coding region of gene (procedure),,,,; instantiatesUri = https://pubmed.ncbi.nlm.nih.gov/33927380/; status = completed; category = Laboratory; performed[x] = 2023-10-01

Genomic Study Referrer Extension: Practitioner Jane Doel

identifier: http://example.org/identifiers/genomicstudies/urn:uuid:1111-1111-1111-1113 (use: temp, )

status: Completed

category: Laboratory

code: Trio Analysis

subject: Child Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 1234-11111 (use: temp, ))

performed: 2023-10-01

asserter: Practitioner Jane Doel

note:

De novo mutation study of the patient. The Prenatal Trio Whole Exome Sequencing (Prenatal Trio WES) test is ordered by a physician and must be accompanied with a consent form and detailed clinical information. In general, the test is used when prenatal imaging detects an anomaly that strongly suggests that there is an underlying genetic etiology. Prenatal Trio WES is often considered only after fetal chromosome microarray analysis has been non-diagnostic.

Source1

{
  "resourceType": "Procedure",
  "id": "genomicstudy-trio2",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study-analysis-ext",
      "valueReference": {
        "reference": "Procedure/genomicstudyanalysis-trio2"
      }
    },
    {
      "url": "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study-referrer-ext",
      "valueReference": {
        "reference": "Practitioner/practitioner02"
      }
    }
  ],
  "identifier": [
    {
      "use": "temp",
      "system": "http://example.org/identifiers/genomicstudies",
      "value": "urn:uuid:1111-1111-1111-1113"
    }
  ],
  "status": "completed",
  "category": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/observation-category",
        "code": "laboratory"
      }
    ]
  },
  "code": {
    "text": "Trio Analysis"
  },
  "subject": {
    "reference": "Patient/denovoChild"
  },
  "performedDateTime": "2023-10-01",
  "asserter": {
    "reference": "Practitioner/practitioner02"
  },
  "note": [
    {
      "text": "De novo mutation study of the patient. The Prenatal Trio Whole Exome Sequencing (Prenatal Trio WES) test is ordered by a physician and must be accompanied with a consent form and detailed clinical information. In general, the test is used when prenatal imaging detects an anomaly that strongly suggests that there is an underlying genetic etiology. Prenatal Trio WES is often considered only after fetal chromosome microarray analysis has been non-diagnostic."
    }
  ]
}